ロード中...
Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886)
BACKGROUND: Selumetinib (AZD6244, ARRY-142886) is a second generation MEK inhibitor that is currently in clinical trials for various solid malignancies. MEK kinase inhibitors are associated with dermatologic toxicities. While reactions affecting the skin, hair and nails to other targeted agents, suc...
保存先:
| 出版年: | Invest New Drugs |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2010
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5691597/ https://ncbi.nlm.nih.gov/pubmed/20978926 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-010-9567-3 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|